|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
1,2-Dipalmitoylphosphatidylcholine inhibits the reaction [Asbestos, Crocidolite results in increased secretion of IL6 protein] |
CTD |
PMID:19041333 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Prnp |
prion protein |
multiple interactions affects folding |
ISO |
Copper affects the reaction [1,2-Dipalmitoylphosphatidylcholine affects the folding of PRNP protein modified form] |
CTD |
PMID:20936829 |
|
NCBI chr 3:119,186,073...119,201,513
Ensembl chr 3:119,177,485...119,203,937
|
|
|
G |
Fech |
ferrochelatase |
affects abundance |
ISO |
FECH protein affects the abundance of 1-palmitoyl-2-docosahexaenoyl-sn-glycero-3-phosphocholine |
CTD |
PMID:29906468 |
|
NCBI chr18:57,945,123...57,978,327
Ensembl chr18:57,945,122...57,979,348
|
|
|
G |
Fech |
ferrochelatase |
affects abundance |
ISO |
FECH protein affects the abundance of 1-palmitoyl-2-linoleoylphosphatidylcholine |
CTD |
PMID:29906468 |
|
NCBI chr18:57,945,123...57,978,327
Ensembl chr18:57,945,122...57,979,348
|
|
|
G |
Nr5a2 |
nuclear receptor subfamily 5, group A, member 2 |
multiple interactions |
ISO |
[NR5A2 gene mutant form results in increased susceptibility to Dietary Fats] which results in increased abundance of 1-oleoyl lysophosphatidylcholine |
CTD |
PMID:29515023 |
|
NCBI chr13:48,313,634...48,433,494
Ensembl chr13:48,316,301...48,433,326
|
|
G |
Smad3 |
SMAD family member 3 |
decreases abundance |
ISO |
SMAD3 protein results in decreased abundance of 1-oleoyl lysophosphatidylcholine |
CTD |
PMID:23034213 |
|
NCBI chr 8:64,126,829...64,236,960
Ensembl chr 8:64,110,039...64,236,960
|
|
|
G |
Agtr1a |
angiotensin II receptor, type 1a |
increases expression |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of AGTR1 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
increases expression |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of ALOX5 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743
|
|
G |
Ccr2 |
C-C motif chemokine receptor 2 |
increases expression |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of CCR2 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 8:123,734,465...123,742,483
Ensembl chr 8:123,734,430...123,742,100
|
|
G |
Cd68 |
Cd68 molecule |
increases expression |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of CD68 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr10:54,381,814...54,383,693
Ensembl chr10:54,381,815...54,383,697
|
|
G |
Crp |
C-reactive protein |
increases expression |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of CRP mRNA |
CTD |
PMID:16386258 |
|
NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
multiple interactions increases phosphorylation |
EXP |
AG 1879 inhibits the reaction [1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased phosphorylation of GJA1 protein]; resveratrol inhibits the reaction [1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased phosphorylation of GJA1 protein] |
CTD |
PMID:24079413 |
|
NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582
|
|
G |
Il1a |
interleukin 1 alpha |
increases expression |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of IL1A mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
increases expression |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of IL1B mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Kcnab2 |
potassium voltage-gated channel subfamily A regulatory beta subunit 2 |
multiple interactions |
EXP |
[KCNAB2 protein co-treated with NADP] results in increased reduction of 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine |
CTD |
PMID:21296056 |
|
NCBI chr 5:162,899,511...162,988,057
Ensembl chr 5:162,901,896...162,988,243
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation multiple interactions |
EXP |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased phosphorylation of MAPK1 protein resveratrol inhibits the reaction [1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:24079413 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
EXP |
resveratrol inhibits the reaction [1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:24079413 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Olr1 |
oxidized low density lipoprotein receptor 1 |
increases expression |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of OLR1 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 4:162,926,436...162,949,057
Ensembl chr 4:162,926,439...162,948,523
|
|
G |
Ptafr |
platelet-activating factor receptor |
affects binding multiple interactions |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine binds to PTAFR protein 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine inhibits the reaction [Platelet Activating Factor binds to PTAFR protein] |
CTD |
PMID:16386258 |
|
NCBI chr 5:144,765,770...144,795,057
Ensembl chr 5:144,765,976...144,795,251
|
|
G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
increases expression |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of PTGS1 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of PTGS2 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Sele |
selectin E |
increases expression increases secretion |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of SELE mRNA 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased secretion of SELE protein |
CTD |
PMID:16386258 |
|
NCBI chr13:76,402,841...76,412,741
Ensembl chr13:76,403,304...76,412,741
|
|
G |
Src |
SRC proto-oncogene, non-receptor tyrosine kinase |
multiple interactions increases phosphorylation |
EXP |
resveratrol inhibits the reaction [1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased phosphorylation of SRC protein] |
CTD |
PMID:24079413 |
|
NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476
|
|
G |
Timp4 |
TIMP metallopeptidase inhibitor 4 |
increases expression |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of TIMP4 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 4:148,306,021...148,312,558
Ensembl chr 4:148,304,490...148,312,558
|
|
G |
Tnf |
tumor necrosis factor |
increases expression increases secretion |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of TNF mRNA 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased secretion of TNF protein |
CTD |
PMID:16386258 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Lipg |
lipase G, endothelial type |
increases hydrolysis |
ISO |
LIPG protein results in increased hydrolysis of 1-O-hexadecyl-2-arachidonyl-sn-glycero-3-phosphocholine |
CTD |
PMID:15953354 |
|
NCBI chr18:68,514,923...68,536,105
Ensembl chr18:68,514,923...68,536,260
|
|
|
G |
Lipc |
lipase C, hepatic type |
multiple interactions |
ISO |
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of stearoyl alpha-lysolecithin |
CTD |
PMID:24777581 |
|
NCBI chr 8:71,509,633...71,635,663
Ensembl chr 8:71,509,635...71,635,464
|
|
G |
Lipg |
lipase G, endothelial type |
multiple interactions |
ISO |
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of stearoyl alpha-lysolecithin |
CTD |
PMID:24777581 |
|
NCBI chr18:68,514,923...68,536,105
Ensembl chr18:68,514,923...68,536,260
|
|
|
G |
Agtr1a |
angiotensin II receptor, type 1a |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of AGTR1 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946
|
|
G |
Alox12 |
arachidonate 12-lipoxygenase, 12S type |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of ALOX12 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr10:54,958,263...54,970,542
Ensembl chr10:54,958,271...54,970,542
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
multiple interactions increases expression |
ISO |
[sodium arsenite co-treated with Platelet Activating Factor co-treated with Arachidonic Acid] results in increased phosphorylation of and results in increased activity of ALOX5 protein; [zileuton results in decreased activity of ALOX5 protein] inhibits the reaction [Calcimycin results in increased abundance of Platelet Activating Factor] Platelet Activating Factor results in increased expression of ALOX5 mRNA |
CTD |
PMID:8387780 PMID:10779545 PMID:16386258 |
|
NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions increases secretion |
ISO |
Foropafant inhibits the reaction [Platelet Activating Factor results in increased secretion of CCL2 protein] |
CTD |
PMID:15149885 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccr2 |
C-C motif chemokine receptor 2 |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of CCR2 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 8:123,734,465...123,742,483
Ensembl chr 8:123,734,430...123,742,100
|
|
G |
Crp |
C-reactive protein |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of CRP mRNA |
CTD |
PMID:16386258 |
|
NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178
|
|
G |
Cx3cr1 |
C-X3-C motif chemokine receptor 1 |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of CX3CR1 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 8:119,785,726...119,799,431
Ensembl chr 8:119,782,595...119,800,014
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions increases abundance |
EXP |
Carbon Tetrachloride promotes the reaction [EDN1 protein results in increased abundance of Platelet Activating Factor]; EDNRB protein affects the reaction [Carbon Tetrachloride promotes the reaction [EDN1 protein results in increased abundance of Platelet Activating Factor]]; EDNRB protein affects the reaction [EDN1 protein results in increased abundance of Platelet Activating Factor] |
CTD |
PMID:18205269 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Ednrb |
endothelin receptor type B |
multiple interactions |
EXP |
EDNRB protein affects the reaction [Carbon Tetrachloride promotes the reaction [EDN1 protein results in increased abundance of Platelet Activating Factor]]; EDNRB protein affects the reaction [EDN1 protein results in increased abundance of Platelet Activating Factor] |
CTD |
PMID:18205269 |
|
NCBI chr15:80,640,839...80,672,115
Ensembl chr15:80,643,043...80,672,115
|
|
G |
Egr1 |
early growth response 1 |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of EGR1 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Gusb |
glucuronidase, beta |
multiple interactions |
EXP |
[Platelet Activating Factor co-treated with Cytochalasin B] results in increased secretion of GUSB protein; IMMLG5521 inhibits the reaction [[Platelet Activating Factor co-treated with Cytochalasin B] results in increased secretion of GUSB protein] |
CTD |
PMID:23850278 |
|
NCBI chr12:26,701,188...26,714,718
Ensembl chr12:26,697,951...26,726,905
|
|
G |
Il1a |
interleukin 1 alpha |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of IL1A mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
increases expression increases secretion multiple interactions |
ISO |
Platelet Activating Factor results in increased expression of IL1B mRNA Platelet Activating Factor results in increased secretion of IL1B protein [Platelet Activating Factor co-treated with MIR149 mRNA] affects the secretion of IL1B protein; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of IL1B protein] |
CTD |
PMID:16386258 PMID:32830409 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions increases secretion |
ISO |
[Platelet Activating Factor co-treated with MIR149 mRNA] affects the secretion of IL6 protein; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of IL6 protein] |
CTD |
PMID:32830409 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Itgam |
integrin subunit alpha M |
multiple interactions increases expression |
ISO |
Foropafant inhibits the reaction [Platelet Activating Factor results in increased expression of ITGAM protein]; Isoproterenol promotes the reaction [Theophylline inhibits the reaction [Platelet Activating Factor results in increased expression of ITGAM protein]]; Theophylline inhibits the reaction [Platelet Activating Factor results in increased expression of ITGAM protein] |
CTD |
PMID:9762784 PMID:11116075 |
|
NCBI chr 1:182,659,047...182,709,501
Ensembl chr 1:182,659,000...182,709,503
|
|
G |
Ltb4r |
leukotriene B4 receptor |
affects response to substance |
ISO |
LTB4R1 protein affects the susceptibility to Platelet Activating Factor |
CTD |
PMID:10934231 |
|
NCBI chr15:29,263,199...29,265,716
|
|
G |
Mmp13 |
matrix metallopeptidase 13 |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of MMP13 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 8:4,497,960...4,508,239
Ensembl chr 8:4,497,960...4,508,239
|
|
G |
Myd88 |
MYD88, innate immune signal transduction adaptor |
increases expression multiple interactions |
ISO |
Platelet Activating Factor results in increased expression of MYD88 protein PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased expression of MYD88 protein] |
CTD |
PMID:32830409 |
|
NCBI chr 8:119,074,439...119,078,508
Ensembl chr 8:119,074,437...119,079,415
|
|
G |
Nceh1 |
neutral cholesterol ester hydrolase 1 |
multiple interactions |
ISO |
NCEH1 protein inhibits the reaction [[Chlorpyrifos metabolite co-treated with Cytidine Diphosphate Choline] results in increased abundance of Platelet Activating Factor] |
CTD |
PMID:18164358 |
|
NCBI chr 2:110,074,985...110,135,592
Ensembl chr 2:110,074,957...110,135,588
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions increases degradation |
ISO |
Acetylcysteine inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; BN 50739 inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; Genistein inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; herbimycin inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; pyrrolidine dithiocarbamic acid inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; Tosylphenylalanyl Chloromethyl Ketone inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; Vitamin E inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein] |
CTD |
PMID:10921504 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Olr1 |
oxidized low density lipoprotein receptor 1 |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of OLR1 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 4:162,926,436...162,949,057
Ensembl chr 4:162,926,439...162,948,523
|
|
G |
Pla2g7 |
phospholipase A2 group VII |
multiple interactions increases expression |
ISO |
[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Platelet Activating Factor] results in increased expression of PLA2G7 mRNA; bepafant inhibits the reaction [Platelet Activating Factor results in increased expression of PLA2G7 mRNA] |
CTD |
PMID:21432021 |
|
NCBI chr 9:17,362,214...17,404,476
Ensembl chr 9:17,362,225...17,404,476
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
decreases expression |
ISO |
Platelet Activating Factor results in decreased expression of PPARA mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Ptafr |
platelet-activating factor receptor |
multiple interactions increases expression increases phosphorylation affects binding |
ISO EXP |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine inhibits the reaction [Platelet Activating Factor binds to PTAFR protein]; BN 50730 inhibits the reaction [Platelet Activating Factor binds to PTAFR protein]; BN 50739 inhibits the reaction [Platelet Activating Factor binds to PTAFR protein]; CMI 392 inhibits the reaction [Platelet Activating Factor binds to PTAFR protein]; MK 287 inhibits the reaction [Platelet Activating Factor binds to PTAFR protein]; zileuton inhibits the reaction [Platelet Activating Factor binds to PTAFR protein] Platelet Activating Factor results in increased expression of PTAFR mRNA Platelet Activating Factor results in increased phosphorylation of PTAFR protein bepafant inhibits the reaction [Platelet Activating Factor results in increased expression of PTAFR mRNA]; Carbon Tetrachloride promotes the reaction [Platelet Activating Factor binds to PTAFR protein]; RGS4 protein inhibits the reaction [Platelet Activating Factor results in increased phosphorylation of PTAFR protein]; TNF protein affects the reaction [Platelet Activating Factor results in increased expression of PTAFR mRNA] |
CTD |
PMID:9065783 PMID:10447766 PMID:11297424 PMID:11529688 PMID:16386258 PMID:18205269 More...
|
|
NCBI chr 5:144,765,770...144,795,057
Ensembl chr 5:144,765,976...144,795,251
|
|
G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of PTGS1 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of PTGS2 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Pvt1 |
Pvt1 oncogene |
increases expression multiple interactions |
ISO |
Platelet Activating Factor results in increased expression of PVT1 mRNA [Platelet Activating Factor co-treated with PVT1 mRNA] affects the expression of MIR149 mRNA; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased expression of MYD88 protein]; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of IL1B protein]; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of IL6 protein]; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of TNF protein] |
CTD |
PMID:32830409 |
|
NCBI chr 7:93,656,528...93,879,938
|
|
G |
Rgs4 |
regulator of G-protein signaling 4 |
multiple interactions |
EXP |
RGS4 protein inhibits the reaction [Platelet Activating Factor results in increased phosphorylation of PTAFR protein] |
CTD |
PMID:11297424 |
|
NCBI chr13:81,936,775...81,943,103
Ensembl chr13:81,936,775...81,943,068
|
|
G |
Sele |
selectin E |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of SELE mRNA |
CTD |
PMID:16386258 |
|
NCBI chr13:76,402,841...76,412,741
Ensembl chr13:76,403,304...76,412,741
|
|
G |
Sell |
selectin L |
multiple interactions increases secretion |
ISO |
Isoproterenol promotes the reaction [Theophylline inhibits the reaction [Platelet Activating Factor results in increased secretion of SELL protein]]; Theophylline inhibits the reaction [Platelet Activating Factor results in increased secretion of SELL protein] |
CTD |
PMID:9762784 |
|
NCBI chr13:76,416,969...76,436,444
Ensembl chr13:76,416,915...76,436,456
|
|
G |
Selp |
selectin P |
multiple interactions increases expression |
ISO |
Foropafant inhibits the reaction [Platelet Activating Factor results in increased expression of SELP protein] |
CTD |
PMID:11116075 |
|
NCBI chr13:76,476,229...76,511,846
Ensembl chr13:76,476,295...76,511,845
|
|
G |
Timp4 |
TIMP metallopeptidase inhibitor 4 |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of TIMP4 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 4:148,306,021...148,312,558
Ensembl chr 4:148,304,490...148,312,558
|
|
G |
Tnf |
tumor necrosis factor |
increases secretion multiple interactions increases expression |
ISO EXP |
Platelet Activating Factor results in increased secretion of TNF protein [Platelet Activating Factor co-treated with MIR149 mRNA] affects the secretion of TNF protein; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of TNF protein] TNF protein affects the reaction [Platelet Activating Factor results in increased expression of PTAFR mRNA] Platelet Activating Factor results in increased expression of TNF mRNA Acetylcysteine inhibits the reaction [Platelet Activating Factor results in increased expression of TNF mRNA]; BN 50739 inhibits the reaction [Platelet Activating Factor results in increased expression of TNF mRNA]; pyrrolidine dithiocarbamic acid inhibits the reaction [Platelet Activating Factor results in increased expression of TNF mRNA]; Vitamin E inhibits the reaction [Platelet Activating Factor results in increased expression of TNF mRNA] |
CTD |
PMID:9065783 PMID:10921504 PMID:16386258 PMID:32830409 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Tnf |
tumor necrosis factor |
increases expression |
EXP |
platelet-activating factor increases expression of Tnf protein in portal stenosis rat plasma |
RGD |
PMID:10452877 |
RGD:38508900 |
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Casp3 |
caspase 3 |
decreases expression |
ISO |
Cytidine Diphosphate Choline results in decreased expression of CASP3 protein |
CTD |
PMID:12443983 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
decreases expression |
EXP |
Cytidine Diphosphate Choline results in decreased expression of ICAM1 mRNA |
CTD |
PMID:16193989 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Nceh1 |
neutral cholesterol ester hydrolase 1 |
multiple interactions |
ISO |
NCEH1 protein inhibits the reaction [[Chlorpyrifos metabolite co-treated with Cytidine Diphosphate Choline] results in increased abundance of Platelet Activating Factor] |
CTD |
PMID:18164358 |
|
NCBI chr 2:110,074,985...110,135,592
Ensembl chr 2:110,074,957...110,135,588
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
decreases expression |
ISO |
Cytidine Diphosphate Choline results in decreased expression of PARP1 protein modified form |
CTD |
PMID:12443983 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Sirt1 |
sirtuin 1 |
increases expression multiple interactions |
EXP |
Cytidine Diphosphate Choline results in increased expression of SIRT1 protein Cytidine Diphosphate Choline results in increased expression of and results in increased activity of SIRT1 protein |
CTD |
PMID:23600725 |
|
NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260
|
|
|
G |
Ache |
acetylcholinesterase |
decreases activity |
ISO |
Echothiophate Iodide results in decreased activity of ACHE protein |
CTD |
PMID:16978018 |
|
NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Alb |
albumin |
affects binding |
ISO |
Echothiophate Iodide binds to ALB protein |
CTD |
PMID:15525694 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Bche |
butyrylcholinesterase |
decreases activity multiple interactions |
ISO |
Echothiophate Iodide results in decreased activity of BCHE protein Echothiophate Iodide inhibits the reaction [BCHE protein results in increased hydrolysis of Butyrylthiocholine] |
CTD |
PMID:7377577 PMID:16213467 PMID:17698511 PMID:21802514 |
|
NCBI chr 2:158,308,674...158,401,148
Ensembl chr 2:158,307,584...158,401,148
|
|
G |
Nceh1 |
neutral cholesterol ester hydrolase 1 |
decreases activity |
ISO |
Echothiophate Iodide results in decreased activity of NCEH1 protein |
CTD |
PMID:16978018 |
|
NCBI chr 2:110,074,985...110,135,592
Ensembl chr 2:110,074,957...110,135,588
|
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
edelfosine inhibits the reaction [Nicotine results in increased phosphorylation of BCL2 protein]; edelfosine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of BCL2 protein]; edelfosine promotes the reaction [Cytarabine results in decreased expression of BCL2 protein] |
CTD |
PMID:9295281 PMID:12421819 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
F2rl1 |
F2R like trypsin receptor 1 |
multiple interactions |
ISO |
edelfosine inhibits the reaction [F2RL1 protein promotes the reaction [allyl isothiocyanate results in increased activity of TRPA1 protein]]; edelfosine inhibits the reaction [F2RL1 protein promotes the reaction [cinnamaldehyde results in increased activity of TRPA1 protein]] |
CTD |
PMID:17571167 |
|
NCBI chr 2:26,772,274...26,785,226
Ensembl chr 2:26,772,278...26,785,226
|
|
G |
Lep |
leptin |
multiple interactions |
ISO |
edelfosine inhibits the reaction [LEP protein results in increased transport of Calcium] |
CTD |
PMID:20107083 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Plcb2 |
phospholipase C, beta 2 |
multiple interactions |
ISO |
edelfosine inhibits the reaction [Cytarabine affects the localization of PLCB2 protein]; edelfosine inhibits the reaction [Tetradecanoylphorbol Acetate affects the localization of PLCB2 protein] |
CTD |
PMID:9295281 |
|
NCBI chr 3:105,683,676...105,704,384
Ensembl chr 3:105,684,815...105,704,302
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression |
ISO |
edelfosine results in increased expression of PTGS2 protein |
CTD |
PMID:12485854 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Trpa1 |
transient receptor potential cation channel, subfamily A, member 1 |
multiple interactions |
ISO |
edelfosine inhibits the reaction [F2RL1 protein promotes the reaction [allyl isothiocyanate results in increased activity of TRPA1 protein]]; edelfosine inhibits the reaction [F2RL1 protein promotes the reaction [cinnamaldehyde results in increased activity of TRPA1 protein]] |
CTD |
PMID:17571167 |
|
NCBI chr 5:4,379,862...4,434,133
Ensembl chr 5:4,379,999...4,433,570
|
|
|
G |
Gdpd5 |
glycerophosphodiester phosphodiesterase domain containing 5 |
affects abundance |
ISO |
GDPD5 protein affects the abundance of Glycerylphosphorylcholine |
CTD |
PMID:33617914 |
|
NCBI chr 1:153,679,718...153,761,452
Ensembl chr 1:153,679,718...153,761,446
|
|
G |
Pnpla6 |
patatin-like phospholipase domain containing 6 |
affects abundance |
ISO |
PNPLA6 protein affects the abundance of Glycerylphosphorylcholine |
CTD |
PMID:36336212 |
|
NCBI chr12:1,574,387...1,603,735
Ensembl chr12:1,560,363...1,603,734
|
|
|
G |
Bmal1 |
basic helix-loop-helix ARNT like 1 |
affects abundance |
ISO |
BMAL1 gene mutant form affects the abundance of Lysophosphatidylcholines |
CTD |
PMID:27056296 |
|
NCBI chr 1:167,331,756...167,430,235
Ensembl chr 1:167,331,633...167,430,231
|
|
G |
Casp3 |
caspase 3 |
increases expression multiple interactions |
ISO |
Lysophosphatidylcholines results in increased expression of CASP3 protein GPR4 protein promotes the reaction [Lysophosphatidylcholines results in increased expression of CASP3 protein] |
CTD |
PMID:34293432 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cav1 |
caveolin 1 |
multiple interactions increases expression |
ISO |
alpha-Tocopherol inhibits the reaction [Lysophosphatidylcholines results in increased expression of CAV1 mRNA]; quercetin 3-O-glucuronide inhibits the reaction [Lysophosphatidylcholines results in increased expression of CAV1 mRNA]; Quercetin inhibits the reaction [Lysophosphatidylcholines results in increased expression of CAV1 mRNA]; Quercetin inhibits the reaction [Lysophosphatidylcholines results in increased expression of CAV1 protein] Lysophosphatidylcholines results in increased expression of CAV1 mRNA; Lysophosphatidylcholines results in increased expression of CAV1 protein |
CTD |
PMID:27257344 |
|
NCBI chr 4:45,640,624...45,673,708
Ensembl chr 4:45,634,918...45,673,705
|
|
G |
Enpp2 |
ectonucleotide pyrophosphatase/phosphodiesterase 2 |
multiple interactions |
ISO |
[[Capsaicin results in increased chemical synthesis of Lysophosphatidylcholines] which results in increased secretion of Lysophosphatidylcholines] promotes the reaction [ENPP2 results in increased chemical synthesis of lysophosphatidic acid]; [ENPP2 protein co-treated with Lysophosphatidylcholines] results in increased chemical synthesis of lysophosphatidic acid |
CTD |
PMID:19014389 |
|
NCBI chr 7:86,202,345...86,325,050
Ensembl chr 7:86,202,350...86,324,827
|
|
G |
Enpp7 |
ectonucleotide pyrophosphatase/phosphodiesterase 7 |
increases hydrolysis |
ISO |
ENPP7 protein results in increased hydrolysis of Lysophosphatidylcholines |
CTD |
PMID:12885774 |
|
NCBI chr10:104,242,169...104,247,185
Ensembl chr10:104,242,223...104,246,589
|
|
G |
Fscn1 |
fascin actin-bundling protein 1 |
increases expression |
ISO |
Lysophosphatidylcholines results in increased expression of FSCN1 mRNA |
CTD |
PMID:22102721 |
|
NCBI chr12:11,597,042...11,610,183
Ensembl chr12:11,597,048...11,610,211
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
increases ubiquitination multiple interactions |
EXP |
Lysophosphatidylcholines results in increased ubiquitination of GJA1 protein Lysophosphatidylcholines affects the localization of and results in increased phosphorylation of GJA1 protein; PRKCE affects the reaction [Lysophosphatidylcholines results in increased phosphorylation of GJA1 protein] |
CTD |
PMID:23973256 |
|
NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582
|
|
G |
Gpr4 |
G protein-coupled receptor 4 |
increases expression multiple interactions |
ISO |
Lysophosphatidylcholines results in increased expression of GPR4 mRNA; Lysophosphatidylcholines results in increased expression of GPR4 protein GPR4 protein promotes the reaction [Lysophosphatidylcholines results in increased expression of CASP3 protein]; GPR4 protein promotes the reaction [Lysophosphatidylcholines results in increased expression of IL18 protein]; GPR4 protein promotes the reaction [Lysophosphatidylcholines results in increased expression of IL1B protein]; GPR4 protein promotes the reaction [Lysophosphatidylcholines results in increased expression of IL33 protein]; GPR4 protein promotes the reaction [Lysophosphatidylcholines results in increased expression of NLRP3 protein] |
CTD |
PMID:34293432 |
|
NCBI chr 1:78,865,376...78,877,126
Ensembl chr 1:78,865,409...78,876,599
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression |
ISO |
Lysophosphatidylcholines results in increased expression of HMOX1 mRNA |
CTD |
PMID:9808084 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
increases expression multiple interactions |
ISO |
Lysophosphatidylcholines results in increased expression of ICAM1 mRNA quercetin 3-O-glucuronide inhibits the reaction [Lysophosphatidylcholines results in increased expression of ICAM1 mRNA]; Quercetin inhibits the reaction [Lysophosphatidylcholines results in increased expression of ICAM1 mRNA] |
CTD |
PMID:27257344 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Il18 |
interleukin 18 |
increases expression multiple interactions |
ISO |
Lysophosphatidylcholines results in increased expression of IL18 protein GPR4 protein promotes the reaction [Lysophosphatidylcholines results in increased expression of IL18 protein] |
CTD |
PMID:34293432 |
|
NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887
|
|
G |
Il1b |
interleukin 1 beta |
increases expression multiple interactions |
ISO |
Lysophosphatidylcholines results in increased expression of IL1B protein GPR4 protein promotes the reaction [Lysophosphatidylcholines results in increased expression of IL1B protein] |
CTD |
PMID:34293432 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il33 |
interleukin 33 |
increases expression multiple interactions |
ISO |
Lysophosphatidylcholines results in increased expression of IL33 protein GPR4 protein promotes the reaction [Lysophosphatidylcholines results in increased expression of IL33 protein] |
CTD |
PMID:34293432 |
|
NCBI chr 1:227,701,964...227,736,374
Ensembl chr 1:227,721,435...227,736,373
|
|
G |
Lama3 |
laminin subunit alpha 3 |
increases expression |
ISO |
Lysophosphatidylcholines results in increased expression of LAMA3 mRNA |
CTD |
PMID:15541073 |
|
NCBI chr18:3,523,168...3,751,722
Ensembl chr18:3,523,133...3,751,353
|
|
G |
Lamb3 |
laminin subunit beta 3 |
increases expression |
ISO |
Lysophosphatidylcholines results in increased expression of LAMB3 mRNA |
CTD |
PMID:15541073 |
|
NCBI chr13:104,833,810...104,875,405
Ensembl chr13:104,833,873...104,875,405
|
|
G |
Lamc2 |
laminin subunit gamma 2 |
increases expression |
ISO |
Lysophosphatidylcholines results in increased expression of LAMC2 mRNA |
CTD |
PMID:15541073 |
|
NCBI chr13:65,284,664...65,344,164
Ensembl chr13:65,284,664...65,344,200
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation |
EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Lysophosphatidylcholines results in increased phosphorylation of MAPK1 protein]; resveratrol inhibits the reaction [Lysophosphatidylcholines results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:20564508 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Lysophosphatidylcholines results in increased phosphorylation of MAPK3 protein]; resveratrol inhibits the reaction [Lysophosphatidylcholines results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:20564508 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mfsd2a |
MFSD2 lysolipid transporter A, lysophospholipid |
increases transport |
ISO |
MFSD2A results in increased transport of Lysophosphatidylcholines |
CTD |
PMID:26005865 |
|
NCBI chr 5:135,225,801...135,240,744
Ensembl chr 5:135,225,816...135,240,690
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions increases expression |
ISO |
GPR4 protein promotes the reaction [Lysophosphatidylcholines results in increased expression of NLRP3 protein] |
CTD |
PMID:34293432 |
|
NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions increases expression |
EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Lysophosphatidylcholines results in increased expression of NOS2 mRNA]; Resveratrol inhibits the reaction [Lysophosphatidylcholines results in increased expression of NOS2 mRNA] |
CTD |
PMID:20564508 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nos3 |
nitric oxide synthase 3 |
multiple interactions decreases expression |
EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Lysophosphatidylcholines results in decreased expression of NOS3 mRNA]; resveratrol inhibits the reaction [Lysophosphatidylcholines results in decreased expression of NOS3 mRNA] |
CTD |
PMID:20564508 |
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Nr5a2 |
nuclear receptor subfamily 5, group A, member 2 |
multiple interactions |
ISO |
[NR5A2 gene mutant form results in increased susceptibility to Dietary Fats] which results in increased abundance of Lysophosphatidylcholines |
CTD |
PMID:29515023 |
|
NCBI chr13:48,313,634...48,433,494
Ensembl chr13:48,316,301...48,433,326
|
|
G |
Pah |
phenylalanine hydroxylase |
multiple interactions |
ISO |
Lysophosphatidylcholines results in increased activity of [PAH protein binds to PAH protein binds to PAH protein binds to PAH protein] |
CTD |
PMID:19367645 |
|
NCBI chr 7:21,933,179...21,998,134
Ensembl chr 7:21,933,179...21,998,130
|
|
G |
Pnpla6 |
patatin-like phospholipase domain containing 6 |
affects abundance |
ISO |
PNPLA6 protein affects the abundance of Lysophosphatidylcholines |
CTD |
PMID:36336212 |
|
NCBI chr12:1,574,387...1,603,735
Ensembl chr12:1,560,363...1,603,734
|
|
G |
Prkce |
protein kinase C, epsilon |
multiple interactions |
EXP |
PRKCE affects the reaction [Lysophosphatidylcholines results in increased phosphorylation of GJA1 protein] |
CTD |
PMID:23973256 |
|
NCBI chr 6:7,965,048...8,451,966
Ensembl chr 6:7,965,048...8,451,719
|
|
G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
decreases expression multiple interactions |
EXP |
Lysophosphatidylcholines results in decreased expression of PTGS1 mRNA 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Lysophosphatidylcholines results in decreased expression of PTGS1 mRNA]; resveratrol inhibits the reaction [Lysophosphatidylcholines results in decreased expression of PTGS1 mRNA] |
CTD |
PMID:20564508 |
|
NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions increases expression |
EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Lysophosphatidylcholines results in increased expression of PTGS2 mRNA]; resveratrol inhibits the reaction [Lysophosphatidylcholines results in increased expression of PTGS2 mRNA] |
CTD |
PMID:20564508 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
ISO |
[TP53 protein mutant form results in increased susceptibility to Niclosamide] which results in increased abundance of Lysophosphatidylcholines |
CTD |
PMID:30258081 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Trpc5 |
transient receptor potential cation channel, subfamily C, member 5 |
multiple interactions |
ISO |
Lysophosphatidylcholines promotes the reaction [TRPC5 protein results in increased transport of Calcium]; resveratrol inhibits the reaction [Lysophosphatidylcholines promotes the reaction [TRPC5 protein results in increased transport of Calcium]] |
CTD |
PMID:21127073 |
|
NCBI chr X:107,946,163...108,230,991
Ensembl chr X:107,939,131...108,230,991
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
increases expression |
ISO |
Lysophosphatidylcholines results in increased expression of VCAM1 mRNA |
CTD |
PMID:27257344 |
|
NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
decreases response to substance multiple interactions |
ISO |
ABCB1 protein results in decreased susceptibility to miltefosine miltefosine binds to and results in decreased activity of ABCB1 protein |
CTD |
PMID:11355955 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Prkca |
protein kinase C, alpha |
decreases phosphorylation |
ISO |
miltefosine results in decreased phosphorylation of PRKCA protein |
CTD |
PMID:31265827 |
|
NCBI chr10:92,889,390...93,288,013
Ensembl chr10:92,894,012...93,288,012
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
increases secretion |
ISO |
ABCB11 protein results in increased secretion of Phosphatidylcholines |
CTD |
PMID:14570929 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
affects export affects transport |
ISO |
ABCB1 protein affects the export of Phosphatidylcholines ABCB1 protein affects the transport of Phosphatidylcholines |
CTD |
PMID:11147995 PMID:11745043 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcb4 |
ATP binding cassette subfamily B member 4 |
affects transport affects export |
ISO |
ABCB4 protein affects the transport of Phosphatidylcholines ABCB4 protein affects the export of Phosphatidylcholines |
CTD |
PMID:11745043 PMID:15696852 |
|
NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202
|
|
G |
Acat1 |
acetyl-CoA acetyltransferase 1 |
decreases activity |
EXP |
Phosphatidylcholines results in decreased activity of ACAT1 protein |
CTD |
PMID:12559476 |
|
NCBI chr 8:53,979,813...54,008,861
Ensembl chr 8:53,979,813...54,008,855
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
decreases expression |
ISO |
Phosphatidylcholines results in decreased expression of ADIPOQ mRNA |
CTD |
PMID:23911798 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions increases abundance |
ISO |
PEMT protein promotes the reaction [AHR protein results in increased abundance of Phosphatidylcholines] |
CTD |
PMID:29416063 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Aifm1 |
apoptosis inducing factor, mitochondria associated 1 |
multiple interactions |
ISO |
[rubitecan co-treated with Phosphatidylcholines] results in increased expression of AIFM1 protein |
CTD |
PMID:21695227 |
|
NCBI chr X:127,650,223...127,689,356
Ensembl chr X:127,650,226...127,689,256
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
ISO |
[[[APP protein modified form binds to Copper] which co-treated with Ascorbic Acid] results in increased oxidation of Phosphatidylcholines] which results in increased chemical synthesis of phosphatidylcholine hydroperoxide; [[APP protein modified form binds to Copper] which co-treated with Ascorbic Acid] results in increased oxidation of Phosphatidylcholines; Edetic Acid inhibits the reaction [[[[APP protein modified form binds to Copper] which co-treated with Ascorbic Acid] results in increased oxidation of Phosphatidylcholines] which results in increased chemical synthesis of phosphatidylcholine hydroperoxide]; Penicillamine inhibits the reaction [[[[APP protein modified form binds to Copper] which co-treated with Ascorbic Acid] results in increased oxidation of Phosphatidylcholines] which results in increased chemical synthesis of phosphatidylcholine hydroperoxide]; Trientine inhibits the reaction [[[[APP protein modified form binds to Copper] which co-treated with Ascorbic Acid] results in increased oxidation of Phosphatidylcholines] which results in increased chemical synthesis of phosphatidylcholine hydroperoxide] |
CTD |
PMID:17964426 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
As3mt |
arsenite methyltransferase |
affects metabolic processing |
ISO |
AS3MT gene mutant form affects the metabolism of Phosphatidylcholines |
CTD |
PMID:27591999 |
|
NCBI chr 1:245,595,939...245,628,921
Ensembl chr 1:245,596,108...245,627,872
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
[rubitecan co-treated with Phosphatidylcholines] results in increased expression of BAX protein |
CTD |
PMID:21695227 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
[rubitecan co-treated with Phosphatidylcholines] results in decreased expression of BCL2 protein |
CTD |
PMID:21695227 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bmal1 |
basic helix-loop-helix ARNT like 1 |
increases abundance |
ISO |
BMAL1 gene mutant form results in increased abundance of Phosphatidylcholines |
CTD |
PMID:27056296 |
|
NCBI chr 1:167,331,756...167,430,235
Ensembl chr 1:167,331,633...167,430,231
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
[rubitecan co-treated with Phosphatidylcholines] results in increased expression of CASP3 protein |
CTD |
PMID:21695227 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
[rubitecan co-treated with Phosphatidylcholines] results in increased expression of CASP8 protein |
CTD |
PMID:21695227 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
ISO |
[rubitecan co-treated with Phosphatidylcholines] results in increased expression of CASP9 protein |
CTD |
PMID:21695227 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
increases expression |
ISO |
Phosphatidylcholines results in increased expression of CCL2 mRNA |
CTD |
PMID:23911798 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
ISO |
[rubitecan co-treated with Phosphatidylcholines] results in decreased expression of CCND1 protein |
CTD |
PMID:21695227 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccne1 |
cyclin E1 |
multiple interactions |
ISO |
Phosphatidylcholines promotes the reaction [rubitecan results in decreased expression of CCNE1 protein] |
CTD |
PMID:21695227 |
|
NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
multiple interactions |
ISO |
[rubitecan co-treated with Phosphatidylcholines] results in decreased expression of CDK2 protein |
CTD |
PMID:21695227 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions |
ISO |
[rubitecan co-treated with Phosphatidylcholines] results in increased expression of CDKN1A protein |
CTD |
PMID:21695227 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
multiple interactions |
ISO |
[rubitecan co-treated with Phosphatidylcholines] results in increased expression of CDKN1B protein |
CTD |
PMID:21695227 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Ces1d |
carboxylesterase 1D |
decreases expression |
ISO |
Phosphatidylcholines results in decreased expression of CES1D mRNA |
CTD |
PMID:23911798 |
|
NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions |
EXP |
[silybin co-treated with Phosphatidylcholines co-treated with Vitamin E] inhibits the reaction [Dimethylnitrosamine results in increased expression of COL1A1 mRNA] |
CTD |
PMID:16169303 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Crp |
C-reactive protein |
affects binding decreases activity |
ISO |
CRP protein binds to Phosphatidylcholines Phosphatidylcholines results in decreased activity of CRP protein |
CTD |
PMID:16962105 |
|
NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
affects activity |
ISO |
Phosphatidylcholines affects the activity of CYP1A2 protein |
CTD |
PMID:15966743 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
increases activity |
EXP |
Phosphatidylcholines results in increased activity of CYP7A1 protein |
CTD |
PMID:12559476 |
|
NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
|
|
G |
Enpp7 |
ectonucleotide pyrophosphatase/phosphodiesterase 7 |
increases hydrolysis |
ISO |
ENPP7 protein results in increased hydrolysis of Phosphatidylcholines |
CTD |
PMID:12885774 |
|
NCBI chr10:104,242,169...104,247,185
Ensembl chr10:104,242,223...104,246,589
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions |
ISO |
[orlistat results in decreased activity of FASN protein] which results in decreased abundance of Phosphatidylcholines |
CTD |
PMID:18723500 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Fgf19 |
fibroblast growth factor 19 |
decreases abundance |
ISO |
FGF19 protein results in decreased abundance of Phosphatidylcholines |
CTD |
PMID:29416063 |
|
NCBI chr 1:200,056,526...200,060,980
Ensembl chr 1:200,056,644...200,060,287
|
|
G |
Gpx4 |
glutathione peroxidase 4 |
multiple interactions |
ISO |
GPX4 mutant form promotes the reaction [TNF protein results in increased abundance of Phosphatidylcholines metabolite]; GPX4 protein inhibits the reaction [TNF protein results in increased abundance of Phosphatidylcholines metabolite] |
CTD |
PMID:22433871 |
|
NCBI chr 7:9,650,186...9,652,982
Ensembl chr 7:9,650,185...9,652,982
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
increases activity |
EXP |
Phosphatidylcholines results in increased activity of HMGCR protein |
CTD |
PMID:12559476 |
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Igf1 |
insulin-like growth factor 1 |
increases degradation |
ISO |
IGF1 protein results in increased degradation of Phosphatidylcholines |
CTD |
PMID:2120207 |
|
NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296
|
|
G |
Il10 |
interleukin 10 |
increases expression |
ISO |
Phosphatidylcholines results in increased expression of IL10 mRNA |
CTD |
PMID:23911798 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il1b |
interleukin 1 beta |
increases expression multiple interactions |
ISO |
Phosphatidylcholines results in increased expression of IL1B mRNA Phosphatidylcholines results in increased expression of and results in increased secretion of IL1B protein |
CTD |
PMID:23911798 PMID:30958839 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
increases expression |
ISO |
Phosphatidylcholines results in increased expression of IL6 mRNA |
CTD |
PMID:23911798 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Lep |
leptin |
decreases expression |
ISO |
Phosphatidylcholines results in decreased expression of LEP mRNA |
CTD |
PMID:23911798 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Lipc |
lipase C, hepatic type |
multiple interactions increases abundance |
ISO |
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of Phosphatidylcholines LIPC gene mutant form results in increased abundance of Phosphatidylcholines |
CTD |
PMID:24777581 |
|
NCBI chr 8:71,509,633...71,635,663
Ensembl chr 8:71,509,635...71,635,464
|
|
G |
Lipe |
lipase E, hormone sensitive type |
increases expression |
ISO |
Phosphatidylcholines results in increased expression of LIPE mRNA |
CTD |
PMID:23911798 |
|
NCBI chr 1:80,965,612...80,984,313
Ensembl chr 1:80,965,627...80,984,310
|
|
G |
Lipg |
lipase G, endothelial type |
multiple interactions increases abundance |
ISO |
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of Phosphatidylcholines LIPG gene mutant form results in increased abundance of Phosphatidylcholines |
CTD |
PMID:24777581 |
|
NCBI chr18:68,514,923...68,536,105
Ensembl chr18:68,514,923...68,536,260
|
|
G |
Ltf |
lactotransferrin |
multiple interactions |
ISO |
[LTF protein co-treated with Phosphatidylcholines co-treated with Phytosterols] inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein] |
CTD |
PMID:16141546 |
|
NCBI chr 8:110,999,948...111,022,795
Ensembl chr 8:110,999,948...111,022,795
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions |
EXP |
[silybin co-treated with Phosphatidylcholines co-treated with Vitamin E] inhibits the reaction [Dimethylnitrosamine results in increased expression of MMP2 mRNA] |
CTD |
PMID:16169303 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Nox4 |
NADPH oxidase 4 |
multiple interactions |
ISO |
NOX4 mutant form inhibits the reaction [TNF protein results in increased abundance of Phosphatidylcholines metabolite] |
CTD |
PMID:22433871 |
|
NCBI chr 1:140,900,886...141,078,844
Ensembl chr 1:140,901,097...141,077,406
|
|
G |
Nr0b2 |
nuclear receptor subfamily 0, group B, member 2 |
decreases abundance |
ISO |
NR0B2 protein results in decreased abundance of Phosphatidylcholines |
CTD |
PMID:29416063 |
|
NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609
|
|
G |
Nr5a2 |
nuclear receptor subfamily 5, group A, member 2 |
multiple interactions |
ISO |
[NR5A2 gene mutant form results in increased susceptibility to Dietary Fats] which results in increased abundance of Phosphatidylcholines |
CTD |
PMID:29515023 |
|
NCBI chr13:48,313,634...48,433,494
Ensembl chr13:48,316,301...48,433,326
|
|
G |
Pafah1b1 |
platelet-activating factor acetylhydrolase 1b, regulatory subunit 1 |
multiple interactions increases secretion |
EXP |
PAFAH1B1 protein promotes the reaction [Terbutaline results in increased secretion of Phosphatidylcholines]; PAFAH1B1 protein promotes the reaction [Tetradecanoylphorbol Acetate results in increased secretion of Phosphatidylcholines] PAFAH1B1 protein results in increased secretion of Phosphatidylcholines |
CTD |
PMID:12013527 |
|
NCBI chr10:59,533,042...59,591,808
Ensembl chr10:59,534,117...59,591,808
|
|
G |
Pafah2 |
platelet-activating factor acetylhydrolase 2 |
multiple interactions |
ISO |
PAFAH2 inhibits the reaction [TNF protein results in increased abundance of Phosphatidylcholines metabolite] |
CTD |
PMID:22433871 |
|
NCBI chr 5:146,607,050...146,636,203
Ensembl chr 5:146,613,498...146,634,943
|
|
G |
Pcyt1a |
phosphate cytidylyltransferase 1A, choline |
multiple interactions |
ISO |
PCYT1A protein promotes the reaction [PLPP6 protein results in increased chemical synthesis of Phosphatidylcholines] |
CTD |
PMID:18930839 |
|
NCBI chr11:68,313,860...68,357,828
Ensembl chr11:68,313,882...68,357,357
|
|
G |
Pemt |
phosphatidylethanolamine N-methyltransferase |
multiple interactions |
ISO |
PEMT protein promotes the reaction [AHR protein results in increased abundance of Phosphatidylcholines] |
CTD |
PMID:29416063 |
|
NCBI chr10:44,775,910...44,849,990
Ensembl chr10:44,775,911...44,850,013
|
|
G |
Plin1 |
perilipin 1 |
increases expression |
ISO |
Phosphatidylcholines results in increased expression of PLIN1 mRNA |
CTD |
PMID:23911798 |
|
NCBI chr 1:133,664,294...133,676,854
Ensembl chr 1:133,664,892...133,676,828
|
|
G |
Plpp6 |
phospholipid phosphatase 6 |
multiple interactions increases chemical synthesis |
ISO |
PCYT1A protein promotes the reaction [PLPP6 protein results in increased chemical synthesis of Phosphatidylcholines] |
CTD |
PMID:18930839 |
|
NCBI chr 1:226,679,100...226,681,952
Ensembl chr 1:226,679,100...226,681,949
|
|
G |
Pnpla2 |
patatin-like phospholipase domain containing 2 |
decreases expression |
ISO |
Phosphatidylcholines results in decreased expression of PNPLA2 mRNA |
CTD |
PMID:23911798 |
|
NCBI chr 1:196,552,723...196,557,805
Ensembl chr 1:196,552,723...196,557,805
|
|
G |
Pnpla6 |
patatin-like phospholipase domain containing 6 |
affects abundance |
ISO |
PNPLA6 protein affects the abundance of Phosphatidylcholines |
CTD |
PMID:36336212 |
|
NCBI chr12:1,574,387...1,603,735
Ensembl chr12:1,560,363...1,603,734
|
|
G |
Pon2 |
paraoxonase 2 |
increases activity increases expression |
ISO |
Phosphatidylcholines results in increased activity of PON2 protein Phosphatidylcholines results in increased expression of PON2 mRNA |
CTD |
PMID:12615656 |
|
NCBI chr 4:33,389,702...33,425,186
Ensembl chr 4:33,389,714...33,425,248
|
|
G |
Pon3 |
paraoxonase 3 |
multiple interactions |
ISO |
Phosphatidylcholines inhibits the reaction [PON3 protein results in increased metabolism of Lovastatin] |
CTD |
PMID:12615656 |
|
NCBI chr 4:33,356,983...33,383,681
Ensembl chr 4:33,349,168...33,383,855
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
increases expression |
ISO |
Phosphatidylcholines results in increased expression of PPARG mRNA |
CTD |
PMID:23911798 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppargc1b |
PPARG coactivator 1 beta |
increases abundance |
ISO |
PPARGC1B results in increased abundance of Phosphatidylcholines |
CTD |
PMID:17932310 |
|
NCBI chr18:54,758,891...54,861,103
Ensembl chr18:54,758,902...54,861,194
|
|
G |
Pten |
phosphatase and tensin homolog |
affects binding multiple interactions |
ISO |
PTEN protein binds to Phosphatidylcholines [TXN protein binds to PTEN protein] inhibits the reaction [PTEN protein binds to Phosphatidylcholines] |
CTD |
PMID:15313215 |
|
NCBI chr 1:230,630,443...230,697,070
Ensembl chr 1:230,630,338...230,696,838
|
|
G |
Retn |
resistin |
decreases expression |
ISO |
Phosphatidylcholines results in decreased expression of RETN mRNA |
CTD |
PMID:23911798 |
|
NCBI chr12:1,710,881...1,712,621
Ensembl chr12:1,710,881...1,712,620
|
|
G |
Sftpa1 |
surfactant protein A1 |
multiple interactions |
ISO |
[SFTPA1 protein polymorphism binds to SFTPA2 protein polymorphism] inhibits the reaction [Adenosine Triphosphate results in increased secretion of Phosphatidylcholines]; Ozone inhibits the reaction [[SFTPA1 protein polymorphism binds to SFTPA2 protein polymorphism] inhibits the reaction [Adenosine Triphosphate results in increased secretion of Phosphatidylcholines]]; Ozone inhibits the reaction [SFTPA1 protein polymorphism inhibits the reaction [Adenosine Triphosphate results in increased secretion of Phosphatidylcholines]] |
CTD |
PMID:15065867 |
|
NCBI chr16:17,008,180...17,011,686
Ensembl chr16:17,008,180...17,011,685
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
EXP |
[silybin co-treated with Phosphatidylcholines co-treated with Vitamin E] inhibits the reaction [Dimethylnitrosamine results in increased expression of TGFB1 mRNA] |
CTD |
PMID:16169303 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
multiple interactions |
EXP |
[silybin co-treated with Phosphatidylcholines co-treated with Vitamin E] inhibits the reaction [Dimethylnitrosamine results in increased expression of TIMP1 mRNA] |
CTD |
PMID:16169303 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases expression increases abundance |
ISO |
GPX4 mutant form promotes the reaction [TNF protein results in increased abundance of Phosphatidylcholines metabolite]; GPX4 protein inhibits the reaction [TNF protein results in increased abundance of Phosphatidylcholines metabolite]; NOX4 mutant form inhibits the reaction [TNF protein results in increased abundance of Phosphatidylcholines metabolite]; PAFAH2 inhibits the reaction [TNF protein results in increased abundance of Phosphatidylcholines metabolite] Phosphatidylcholines results in increased expression of TNF mRNA [LTF protein co-treated with Phosphatidylcholines co-treated with Phytosterols] inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Phosphatidylcholines results in increased expression of and results in increased secretion of TNF protein |
CTD |
PMID:16141546 PMID:22433871 PMID:23911798 PMID:30958839 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
ISO |
Phosphatidylcholines inhibits the reaction [rubitecan results in increased expression of TP53 protein] |
CTD |
PMID:21695227 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Txn1 |
thioredoxin 1 |
multiple interactions |
ISO |
[TXN protein binds to PTEN protein] inhibits the reaction [PTEN protein binds to Phosphatidylcholines] |
CTD |
PMID:15313215 |
|
NCBI chr 5:72,712,334...72,724,564
Ensembl chr 5:72,711,933...72,724,629
|
|
|
G |
Dek |
DEK proto-oncogene |
decreases chemical synthesis |
ISO |
DEK protein results in decreased chemical synthesis of Phosphorylcholine |
CTD |
PMID:28558019 |
|
NCBI chr17:17,580,804...17,602,825
Ensembl chr17:17,580,843...17,602,808
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions |
ISO |
[Cerulenin results in decreased activity of FASN protein] which results in decreased abundance of Phosphorylcholine; [orlistat results in decreased activity of FASN protein] which results in decreased abundance of Phosphorylcholine |
CTD |
PMID:18723500 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Hsf1 |
heat shock transcription factor 1 |
increases activity |
ISO |
Phosphorylcholine results in increased activity of HSF1 protein |
CTD |
PMID:34170685 |
|
NCBI chr 7:108,196,040...108,223,011
Ensembl chr 7:108,196,056...108,223,011
|
|
G |
Mmp1 |
matrix metallopeptidase 1 |
multiple interactions increases expression |
ISO |
Genistein inhibits the reaction [Phosphorylcholine analog results in increased expression of MMP1 mRNA]; herbimycin inhibits the reaction [Phosphorylcholine analog results in increased expression of MMP1 mRNA] |
CTD |
PMID:15878362 |
|
NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
increases expression multiple interactions |
ISO |
Phosphorylcholine analog results in increased expression of TIMP1 mRNA Genistein inhibits the reaction [Phosphorylcholine analog results in increased expression of TIMP1 mRNA]; herbimycin inhibits the reaction [Phosphorylcholine analog results in increased expression of TIMP1 mRNA] |
CTD |
PMID:15878362 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Tnf |
tumor necrosis factor |
increases expression |
ISO |
Phosphorylcholine analog results in increased expression of TNF mRNA |
CTD |
PMID:15878362 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Dek |
DEK proto-oncogene |
decreases chemical synthesis |
ISO |
DEK protein results in decreased chemical synthesis of Phosphorylcholine |
CTD |
PMID:28558019 |
|
NCBI chr17:17,580,804...17,602,825
Ensembl chr17:17,580,843...17,602,808
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions |
ISO |
[Cerulenin results in decreased activity of FASN protein] which results in decreased abundance of Phosphorylcholine; [orlistat results in decreased activity of FASN protein] which results in decreased abundance of Phosphorylcholine |
CTD |
PMID:18723500 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Hsf1 |
heat shock transcription factor 1 |
increases activity |
ISO |
Phosphorylcholine results in increased activity of HSF1 protein |
CTD |
PMID:34170685 |
|
NCBI chr 7:108,196,040...108,223,011
Ensembl chr 7:108,196,056...108,223,011
|
|
G |
Mmp1 |
matrix metallopeptidase 1 |
multiple interactions increases expression |
ISO |
Genistein inhibits the reaction [Phosphorylcholine analog results in increased expression of MMP1 mRNA]; herbimycin inhibits the reaction [Phosphorylcholine analog results in increased expression of MMP1 mRNA] |
CTD |
PMID:15878362 |
|
NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
increases expression multiple interactions |
ISO |
Phosphorylcholine analog results in increased expression of TIMP1 mRNA Genistein inhibits the reaction [Phosphorylcholine analog results in increased expression of TIMP1 mRNA]; herbimycin inhibits the reaction [Phosphorylcholine analog results in increased expression of TIMP1 mRNA] |
CTD |
PMID:15878362 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Tnf |
tumor necrosis factor |
increases expression |
ISO |
Phosphorylcholine analog results in increased expression of TNF mRNA |
CTD |
PMID:15878362 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|